Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients.
Georgin-Lavialle S, Terrier B, Guedon AF, Heiblig M, Comont T, Lazaro E, Lacombe V, Terriou L, Ardois S, Bouaziz JD, Mathian A, Le Guenno G, Aouba A, Outh R, Meyer A, Roux-Sauvat M, Ebbo M, Zhao LP, Bigot A, Jamilloux Y, Guillotin V, Flamarion E, Henneton P, Vial G, Jachiet V, Rossignol J, Vinzio S, Weitten T, Vinit J, Deligny C, Humbert S, Samson M, Magy-Bertrand N, Moulinet T, Bourguiba R, Hanslik T, Bachmeyer C, Sebert M, Kostine M, Bienvenu B, Biscay P, Liozon E, Sailler L, Chasset F, Audemard-Verger A, Duroyon E, Sarrabay G, Borlot F, Dieval C, Cluzeau T, Marianetti P, Lobbes H, Boursier G, Gerfaud-Valentin M, Jeannel J, Servettaz A, Audia S, Larue M, Henriot B, Faucher B, Graveleau J, de Sainte Marie B, Galland J, Bouillet L, Arnaud C, Ades L, Carrat F, Hirsch P, Fenaux P, Fain O, Sujobert P, Kosmider O, Mekinian A; French VEXAS group; GFEV, GFM, CEREMAIA, MINHEMON. Georgin-Lavialle S, et al. Among authors: kosmider o. Br J Dermatol. 2022 Mar;186(3):564-574. doi: 10.1111/bjd.20805. Epub 2021 Nov 28. Br J Dermatol. 2022. PMID: 34632574 Free article.
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).
Kosmider O, Gelsi-Boyer V, Cheok M, Grabar S, Della-Valle V, Picard F, Viguié F, Quesnel B, Beyne-Rauzy O, Solary E, Vey N, Hunault-Berger M, Fenaux P, Mansat-De Mas V, Delabesse E, Guardiola P, Lacombe C, Vainchenker W, Preudhomme C, Dreyfus F, Bernard OA, Birnbaum D, Fontenay M; Groupe Francophone des Myélodysplasies. Kosmider O, et al. Blood. 2009 Oct 8;114(15):3285-91. doi: 10.1182/blood-2009-04-215814. Epub 2009 Aug 7. Blood. 2009. PMID: 19666869 Free article.
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.
Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O, Quesnel B, Vey N, Gelsi-Boyer V, Raynaud S, Preudhomme C, Adès L, Fenaux P, Fontenay M; Groupe Francophone des Myelodysplasies (GFM). Itzykson R, et al. Among authors: kosmider o. Leukemia. 2011 Jul;25(7):1147-52. doi: 10.1038/leu.2011.71. Epub 2011 Apr 15. Leukemia. 2011. PMID: 21494260
Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes.
Le Pogam C, Krief P, Beurlet S, Soulié A, Balitrand N, Cassinat B, Cavé H, Kosmider O, Setterblad N, Leboeuf C, Sarda-Mantel L, Hervatin F, Merlet P, Noguera ME, Janin A, Pla M, Fontenay M, Adès L, Fenaux P, Chomienne C, Padua RA, Omidvar N. Le Pogam C, et al. Among authors: kosmider o. Leuk Res. 2013 Mar;37(3):312-9. doi: 10.1016/j.leukres.2012.10.018. Epub 2012 Nov 12. Leuk Res. 2013. PMID: 23153525
An miRNA-DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia.
Solly F, Koering C, Mohamed AM, Maucort-Boulch D, Robert G, Auberger P, Flandrin-Gresta P, Adès L, Fenaux P, Kosmider O, Tavernier-Tardy E, Cornillon J, Guyotat D, Campos L, Mortreux F, Wattel E. Solly F, et al. Among authors: kosmider o. Clin Cancer Res. 2017 Jun 15;23(12):3025-3034. doi: 10.1158/1078-0432.CCR-16-2304. Epub 2016 Nov 23. Clin Cancer Res. 2017. PMID: 27881579
A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome.
Bondu S, Alary AS, Lefèvre C, Houy A, Jung G, Lefebvre T, Rombaut D, Boussaid I, Bousta A, Guillonneau F, Perrier P, Alsafadi S, Wassef M, Margueron R, Rousseau A, Droin N, Cagnard N, Kaltenbach S, Winter S, Kubasch AS, Bouscary D, Santini V, Toma A, Hunault M, Stamatoullas A, Gyan E, Cluzeau T, Platzbecker U, Adès L, Puy H, Stern MH, Karim Z, Mayeux P, Nemeth E, Park S, Ganz T, Kautz L, Kosmider O, Fontenay M. Bondu S, et al. Among authors: kosmider o. Sci Transl Med. 2019 Jul 10;11(500):eaav5467. doi: 10.1126/scitranslmed.aav5467. Sci Transl Med. 2019. PMID: 31292266 Free PMC article. Clinical Trial.
Severe Joint Involvement in VEXAS Syndrome: A Case Report.
Lacombe V, Kosmider O, Prévost M, Lavigne C, Urbanski G. Lacombe V, et al. Among authors: kosmider o. Ann Intern Med. 2021 Jul;174(7):1025-1027. doi: 10.7326/L21-0023. Epub 2021 Mar 30. Ann Intern Med. 2021. PMID: 33780294 No abstract available.
Myeloproliferative neoplasms and clonal haematopoiesis in patients with giant cell arteritis: a case-control and exploratory study.
Papo M, Friedrich C, Delaval L, Boysson H, Viallard JF, Bachmeyer C, Sené T, Humbert S, Duffau P, Contis A, Agard C, Gombert B, Puyade M, Foucher A, Alary AS, Danlos FX, Régent A, Mouthon L, Guillevin L, Samson M, Kosmider O, Terrier B; French Vasculitis Study Group. Papo M, et al. Among authors: kosmider o. Rheumatology (Oxford). 2022 Feb 2;61(2):775-780. doi: 10.1093/rheumatology/keab337. Rheumatology (Oxford). 2022. PMID: 33836046
148 results